ArticleArthritis care & research2017
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
Article in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Oxidative Stress and NRF2-Mediated Redox Regulation in Incomplete Systemic Lupus Erythematosus and Systemic Lupus Erythematosus.Antioxidants (Basel, Switzerland) · 2026Article
- Distinct IgM and IgG autoantibody profiles characterize incomplete and classified systemic autoimmune diseases.Frontiers in immunology · 2026Article
- Article
- REDEFINING AUTOIMMUNE DISEASES: THE OPPORTUNITY FOR PRECISION AND PREVENTION.Transactions of the American Clinical and Climatological Association · 2025Review
- Genetic load in incomplete lupus erythematosus.Lupus science & medicine · 2023Article
- The Psychosocial Impact of Undifferentiated Connective Tissue Disease on Patient Health and Well-Being: A Qualitative Study.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2022Article
- Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals.Frontiers in immunology · 2022Article
- A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.Rheumatology (Oxford, England) · 2021Article
- A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.ACR open rheumatology · 2021Article
- Scabies, incomplete lupus erythematosus and Henoch-Schonlein purpura.Archives of medical science : AMS · 2021Article
- Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity.Nature communications · 2020Article
- Proportions of B-cell subsets are altered in incomplete systemic lupus erythematosus and correlate with interferon score and IgG levels.Rheumatology (Oxford, England) · 2020Article
- Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.RMD open · 2020Article
- Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?Arthritis care & research · 2020Review
- Finding lupus in the ANA haystack.Lupus science & medicine · 2020Review
- Perspective: The Lung, Particles, Fibers, Nanomaterials, and Autoimmunity.Frontiers in immunology · 2020Review
- Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Shared and unique immune alterations in pre-clinical autoimmunity.Current opinion in immunology · 2019Review
- Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial.Arthritis care & research · 2019Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
objectiveIncomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for systemic lupus erythematosus (SLE) classification. Because the nature of ILE is poorly understood and no treatment recommendations exist, we examined the clinical manifestations, medication history, and immunologic features in a diverse collection of ILE and SLE patients.
methodsMedical records of subjects enrolled in the Lupus Family Registry and Repository were reviewed for medication history and American College of Rheumatology (ACR) classification criteria to identify ILE patients (3 ACR criteria; n = 440) and SLE patients (≥4 ACR criteria; n = 3,397). Participants completed the Connective Tissue Disease Screening Questionnaire. Anticardiolipin and plasma B lymphocyte stimulator (BLyS) were measured by enzyme-linked immunosorbent assay, antinuclear antibodies (ANAs) by indirect immunofluorescence, and 13 autoantibodies by bead-based assays.
resultsOn average, ILE patients were older than SLE patients (46.2 years versus 42.0 years; P < 0.0001), and fewer ILE patients were African American (23.9% versus 32.2%; P < 0.001). ILE patients exhibited fewer autoantibody specificities than SLE patients (1.3 versus 2.6; P < 0.0001) and were less likely to have ANA titers ≥1:1,080 (10.5% versus 19.5%; P < 0.0001). BLyS levels were intermediate in ILE patients (controls < ILE; P = 0.016; ILE < SLE; P = 0.008). Pericarditis, renal, or neurologic manifestations occurred in 12.5% of ILE patients and were associated with non-European American race/ethnicity (P = 0.012). Hydroxychloroquine use increased over time, but was less frequent in ILE than SLE patients (65.2% versus 83.1%; P < 0.0001).
conclusionAlthough usually characterized by milder symptoms, ILE manifestations may require immunomodulatory treatments. Longitudinal studies are necessary to understand how ILE affects organ damage and future SLE risk, and to delineate molecular pathways unique to ILE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.